A Two-part, Single and Multiple Dose, Parallel Group Study to Assess Safety and Pharmacokinetics of Oral HTL0018318 in Healthy Japanese and Caucasian Subjects
Latest Information Update: 17 Jan 2020
Price :
$35 *
At a glance
- Drugs HTL 18318 (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Acronyms HTL0018318
- Sponsors Heptares Therapeutics
- 06 Sep 2017 Status changed from active, no longer recruiting to completed.
- 28 Jun 2017 New trial record